<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02674152</url>
  </required_header>
  <id_info>
    <org_study_id>1336.1</org_study_id>
    <secondary_id>2014-005395-28</secondary_id>
    <nct_id>NCT02674152</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of BI 836880 in Patients With Solid Tumors</brief_title>
  <official_title>A First-in Human Phase I, Non-randomised, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Repeated Intravenous Infusions in Patients With Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a Phase I, non-randomized, uncontrolled, open-label, dose escalating study of BI&#xD;
      836880 administered intravenously. The eligible patient population will be patients with&#xD;
      advanced solid tumours. At any time during the trial, it will not be permitted to escalate to&#xD;
      a dose which does not fulfil the escalation with overdose control (EWOC) criterion&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2016</start_date>
  <completion_date type="Actual">November 4, 2020</completion_date>
  <primary_completion_date type="Actual">September 12, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint to assess the maximum tolerated dose (MTD) is based on the number of patients presenting dose-limiting toxicities (DLTs) using CTCAE v4.03, judged to be related to the study medication evaluated over the first cycle of treatment.</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients experiencing drug related AE leading to dose reduction or discontinuation from start of treatment until end of treatment</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure measures (AUC0-tz) after the first dose</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disposition kinetic measures (t1/2 ) after the first dose</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BI 836880</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 836880</intervention_name>
    <arm_group_label>BI 836880</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignancy which is locally advanced or&#xD;
             metastatic solid tumor, and either refractory after standard therapy for the disease&#xD;
             or for which standard therapy is not reliably effective, e.g. they do not tolerate or&#xD;
             have contraindications to otherwise available standard therapy and tumour lesions&#xD;
             evaluable for Dynamic contrast-enhanced (DCE)-MRI at MTD.&#xD;
&#xD;
          -  ECOG performance status &lt;= 2&#xD;
&#xD;
          -  Adequate hepatic, renal and bone marrow functions&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
          -  Life expectancy min. 3 months in the opinion of the investigator&#xD;
&#xD;
          -  Recovery from all reversible adverse events of previous anti-cancer therapies to&#xD;
             baseline or CTCAE grade 1, except for alopecia (any grade) sensory peripheral&#xD;
             neuropathy CTCAE grade &lt;= 2 or considered not clinically significant.&#xD;
&#xD;
          -  adequate contraception by male and female patient during the trial and for at least 6&#xD;
             months after end of treatment.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Known hypersensitivity to the trial drugs or their excipients&#xD;
&#xD;
          -  Current or prior treatment with any systemic anti-cancer therapy either within 28 days&#xD;
             or a minimum of 5 half-lives, whichever is shorter of trial onset.&#xD;
&#xD;
          -  Serious concomitant disease, especially those affecting compliance with trial&#xD;
             requirements or which are considered relevant for the evaluation of the endpoints of&#xD;
             the trial drug&#xD;
&#xD;
          -  Major injuries and/or surgery or bone fracture within 4 weeks of start of treatment,&#xD;
             or planned surgical procedures during the trial period.&#xD;
&#xD;
          -  patients with personal or family history of QT prolongation and/or long QT syndrome,&#xD;
             or prolonged QTcF at baseline (&gt; 470 ms). QTcF will be calculated by Investigator as&#xD;
             the mean of the 3 ECGs taken at screening.&#xD;
&#xD;
          -  Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension,&#xD;
             unstable angina, history of infarction within past 6 months, congestive heart failure&#xD;
             &gt; NYHA II). Uncontrolled hypertension defined as: blood pressure in rested and relaxed&#xD;
             condition &gt;=140 mmHg systolic, or &gt;=90 mmHg diastolic (with or without medication),&#xD;
             measured according to protocol.&#xD;
&#xD;
          -  History of severe haemorrhagic or thromboembolic event in the past 12 months&#xD;
             (excluding central venous catheter thrombosis and peripheral deep vein thrombosis).&#xD;
&#xD;
          -  Known inherited predisposition to bleeding or to thrombosis in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Patient with brain metastases that are symptomatic and/or require therapy.&#xD;
&#xD;
          -  Patients who require full-dose anticoagulation (according to local guidelines).&#xD;
&#xD;
          -  Active alcohol or drug abuse in the opinion of the investigator.&#xD;
&#xD;
          -  Patients who are under judicial protection and patients who are legally&#xD;
             institutionalized.&#xD;
&#xD;
          -  Patients unable or unwilling to comply with protocol&#xD;
&#xD;
          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INS Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

